Related Experiment Video
Updated: Dec 6, 2025
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
18.3K
Systemic lupus erythematosus (SLE): emerging therapeutic targets
Lauren M Mathias1, William Stohl1
1Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine , Los Angeles, CA, USA.
Expert Opinion on Therapeutic Targets
|October 9, 2020
Summary
New therapies targeting the immune system show promise for Systemic Lupus Erythematosus (SLE), an autoimmune disease. Research focuses on diverse immune targets despite challenges in SLE treatment development.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with multifactorial etiologies.
- Its heterogeneous presentation and diverse pathogenesis present significant challenges for therapeutic development.
- Recent advancements have identified numerous novel therapeutic targets within the last decade.
Purpose of the Study:
- To review current and emerging therapeutic targets for Systemic Lupus Erythematosus (SLE).
- To discuss targets within both the adaptive and innate immune systems.
- To provide an overview of key findings, challenges, and future directions in SLE drug development.
Main Methods:
- A comprehensive literature review was conducted using the PubMed database up to April 2020.
- The review focused on therapeutic targets identified in the adaptive and innate immune systems.
- Specific targets discussed include B cell antigens, Bruton's tyrosine kinase, and cytokine/signaling pathways.
Main Results:
- Multiple novel therapeutic targets in SLE have been identified, with many candidate drugs in development.
- Key targets include B cell surface antigens, B cell survival factors, Bruton's tyrosine kinase, costimulators, IL-12/IL-23, calcineurin, JAK/STAT, and interferons.
- Despite challenges, research into targeted SLE therapies is progressing.
Conclusions:
- An improved understanding of SLE pathophysiology has led to promising new therapeutic strategies.
- Targeting specific immune pathways offers potential for more effective SLE treatments.
- Ongoing research aims to overcome limitations in SLE modeling and outcome measures for better therapeutic outcomes.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
10.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.9K
01:29Autoimmune Disorders
1.2K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
1.2K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.6K
01:24T Cell Types and Functions
1.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K
01:26Targets for Drug Action: Overview
9.7K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.7K
02:57Targeted Cancer Therapies
8.3K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.3K